Delivery Order SPE2DB24D2100-SPE2DB25FBGAN
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,131.87. This is a firm fixed-price delivery order with an ultimate completion date of September 25, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. No set-aside designation was used in this award, indicating...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $2,263.74. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order valued at $3,988.39 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Jatenzo 237 mg capsules (120 count) at a ceiling value of $2,263.74. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The ultimate completion date is set for August 19, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,636.67. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120 count) under a firm fixed-price contract with a ceiling value of $1,131.87. The contract, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $14,035.64 to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120-count units) on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on September 24, 2025, for 120 capsules of Jatenzo 237 mg, a testosterone replacement therapy medication, with a ceiling value of $1,724.77. The contract is a firm fixed price delivery order with an ultimate completion date of September 25, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award carries no set-aside designation and was competitively awarded...
- The Defense Logistics Agency awarded a delivery order valued at $1,256.92 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 158 mg on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed-price, competitively awarded contract represents a small-value pharmaceutical delivery with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $7,455.86 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on September 23, 2025, with completion expected by September 24, 2025. This firm fixed-price, non-set-aside contract is a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGANDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Jatenzo 237 mg capsules (120 count) valued at $1,640.34. This firm fixed-price delivery order, which is scheduled for completion by August 27, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999 IDC with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and enables the company to supply a broad range of pharmaceutical products and medical supplies globally to support military healthcare programs. Jatenzo is a testosterone replacement therapy medication used in hormone treatment protocols. The transaction exemplifies AmerisourceBergen's role as a key vendor within DLA's pharmaceutical supply chain, fulfilling federal healthcare requirements across multiple therapeutic domains through competitively awarded, firm fixed-price delivery orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 8/26/25 |